457 related articles for article (PubMed ID: 32580338)
1. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Kooshkaki O; Derakhshani A; Hosseinkhani N; Torabi M; Safaei S; Brunetti O; Racanelli V; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580338
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
4. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
5. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
6. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Rotte A
J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
8. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
10. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Carlino MS; Long GV
Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
[TBL] [Abstract][Full Text] [Related]
14. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.
Rijavec E; Indini A; Ghidini M; Tomasello G; Cattaneo M; Barbin F; Grossi F
Expert Rev Anticancer Ther; 2021 Jul; 21(7):705-713. PubMed ID: 33719827
[TBL] [Abstract][Full Text] [Related]
16. The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4.
Parvini S; Majidpoor J; Mortezaee K
Pathol Res Pract; 2023 Jul; 247():154583. PubMed ID: 37267723
[TBL] [Abstract][Full Text] [Related]
17. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
[TBL] [Abstract][Full Text] [Related]
18. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
Uhara H; Itakura E
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
[TBL] [Abstract][Full Text] [Related]
20. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M; Moreno V; Heinhuis KM; Olszanski AJ; Spreafico A; Ong M; Chu Q; Carvajal RD; Trigo J; Ochoa de Olza M; Provencio M; De Vos FY; De Braud F; Leong S; Lathers D; Wang R; Ravindran P; Feng Y; Aanur P; Melero I
Clin Cancer Res; 2021 Jan; 27(2):460-472. PubMed ID: 33148673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]